[Infostock Daily= Reporter Park Sang-In] GC Green Cross Cell announced that `Immuncell-LC’s three-phase clinical trial plan(IND) for pancreatic cancer submitted to the Ministry of Food and Drug Safety on the 6th.
Three-phase clinical trials are commercialization clinical trials for adding new indications of Immuncell-LC. The goal is to evaluate the effectiveness and safety of 454 pancreatic cancer patients to prove the superiority of the Immuncell-LC and Gemcitabine combined treatment groups over the standard treatment Gemcitabine monotherapy group.
Pancreatic cancer is difficult to detect early due to its long-term characteristics, and 32.8% of people in their 70s are found to have the highest incidence. In the order of 25.4 percent in their 60s and 19.4 percent in their 80s and older, anti-cancer treatments are also very difficult. In fact, pancreatic cancer has a relative survival rate of 12.2 percent for five years, the lowest among the 10 major cancers, and is an intractable disease with little improvement in the development of medical technology.
The goal of this clinical trial is to reduce the recurrence rate and progression rate of cancer and increase the survival rate by administering the standard treatment `Gemcitabine’ and Immuncell-LC in combination.
In the future, 14 other clinical institutions, including Seoul National University Hospital, will plan to recruit 454 pancreatic cancer patients and conduct a extensive three-phase clinical trial.
Reporter Park Sang-In si2020@infostock.co.kr
